Pharmaceutical Representative Office Setup in Dubai

Dubai sits at the centre of a USD 8.7 billion Gulf pharmaceutical market, and a Representative Office is the most direct, low-overhead structure for a foreign pharma company to establish a licensed presence without trading locally. Activity code 7010.98 — Pharmaceutical Representative Office — gives international companies a defined, compliant route into the UAE market for promotion and regulatory engagement, without the complexity of a full commercial entity.

This guide covers the regulatory landscape, what the structure permits, the licence setup steps, and the practical costs and timelines involved.

Key Stats at a Glance

Activity Code	7010.98
Activity Name	Pharmaceutical Representative Office
ISIC Classification	Division 70 — Activities of Head Offices
Licence Type	Commercial / Representative Office
Regulatory Bodies	Dubai Health Authority (DHA), Ministry of Health and Prevention (MOHAP), Dubai Economy and Tourism (DET)
Minimum Share Capital	No minimum for representative office structure
Operational Scope	Promotion and liaison only — no direct sales or import
Foreign Ownership	100% permissible — no local sponsor required

Authoritative Sources: MOHAP Drug Registration | Dubai Health Authority | Dubai Economy and Tourism

What a Pharmaceutical Representative Office Actually Does

Activity code 7010.98 sits within ISIC Division 70, which covers activities of head offices and holding companies — not manufacturing, retail, or distribution. This classification is deliberate and consequential. A representative office operates as an extension of the foreign parent company, not as an independent trading entity in the UAE.

Permitted activities under this structure include medical detailing to licensed healthcare practitioners, regulatory liaison with MOHAP and DHA, market intelligence gathering, and coordination support for clinical trial submissions. The office can represent the parent company's product portfolio and facilitate regulatory submissions — but it cannot invoice, import, or distribute pharmaceutical products directly.

The distinction between a representative office and a full commercial licence matters significantly for compliance. Operating outside the permitted scope — for example, concluding sales contracts locally — exposes the entity to regulatory action from both DET and MOHAP. Understanding the boundary before you set up is not optional.

Regulatory Framework and Approvals

Three bodies govern this structure. Each has a distinct role, and none can be bypassed.

Key Regulatory Bodies

• MOHAP — The Ministry of Health and Prevention governs pharmaceutical product registration and representative office approvals at the federal level. Any engagement in product promotion or regulatory submissions requires MOHAP representative office registration. Visit mohap.gov.ae for current fee schedules and application requirements.
• DHA — The Dubai Health Authority has oversight over any healthcare marketing or engagement with DHA-licensed practitioners operating within Dubai. If your medical detailing activity targets Dubai-based clinicians, DHA compliance is part of the picture. Visit dha.gov.ae.
• DET — Dubai Economy and Tourism issues the trade licence under activity code 7010.98 and handles commercial registration. This is the primary licence-issuing authority for mainland Dubai entities. Visit dubaided.gov.ae.

The foreign parent company must provide a notarised and UAE embassy-attested board resolution authorising the establishment of the representative office, along with an attested certificate of incorporation and recent audited financials. Under current UAE commercial law, a representative office does not require a local sponsor — 100% foreign ownership is permissible.

Step-by-Step Licence Setup Guide

The process is sequential. Skipping steps or submitting incomplete documents is the primary cause of delays.

• Step 1 — Confirm the structure. Verify that a representative office — not a branch or LLC — matches your operational intent. If you anticipate any local revenue generation, a different licence category applies.
• Step 2 — Reserve your trade name. Submit a trade name reservation with DET. The name should reflect the parent company and the pharmaceutical nature of the business. Generic names are typically rejected.
• Step 3 — Prepare parent company documents. Gather the certificate of incorporation, board resolution authorising the Dubai office, and audited financials. All documents must be notarised in the country of origin and attested at UAE embassy level before submission.
• Step 4 — Submit the initial DET application. File the application with activity code 7010.98 and all supporting documents. DET will review and issue initial approval before the licence is finalised.
• Step 5 — Obtain MOHAP approval. If the office will engage in product promotion or regulatory submissions, apply for MOHAP representative office registration in parallel with or immediately following DET initial approval.
• Step 6 — Secure office space. An Ejari-registered tenancy contract is required for DET licence finalisation. Virtual offices do not satisfy this requirement for most pharmaceutical activities.
• Step 7 — Collect the trade licence and register with the Chamber of Commerce. Once the licence is issued, register with the Dubai Chamber to complete commercial standing. Proceed to open a corporate bank account.
• Step 8 — Apply for employee residence visas. Visa quota is linked to office square footage. Plan your space accordingly if you intend to bring in a team from the outset.

Costs, Timelines, and Practical Considerations

Government fees for a DET trade licence under this activity vary by office size and exact activity configuration. Budget AED 15,000–30,000 for initial government fees, excluding professional service charges. MOHAP representative office registration carries a separate federal fee — confirm the current schedule directly at mohap.gov.ae before finalising your budget.

Timeline for a straightforward application with complete, correctly attested documents is typically four to eight weeks. The most common source of delay is incomplete attestation on parent company documents. If your home jurisdiction has a multi-step apostille or embassy process, build in additional time.

Banking deserves separate attention. Pharmaceutical sector entities routinely trigger enhanced due diligence from UAE banks. Allow six to ten weeks for corporate account opening, and approach multiple banks simultaneously. Account opening is not guaranteed — a clean compliance record for the parent company and a well-documented business plan materially improve the outcome.

Both the DET licence and the MOHAP registration require annual renewal. Non-renewal of either creates a compliance gap that can affect visa status and the legal standing of the office. Calendar these renewals well in advance.

Conclusion

A pharmaceutical representative office under activity code 7010.98 gives a foreign pharma company a legitimate, low-complexity Dubai presence for promotion and regulatory engagement — without the overhead of a full trading entity. The structure works precisely because its scope is narrow; staying within that scope is what keeps it clean.

The regulatory requirements across DET, MOHAP, and DHA are manageable, but they are sequential and interdependent. Document preparation, particularly parent company attestation, is where most timelines slip. Get that right early and the rest of the process moves predictably.

If you are assessing whether a representative office or a full commercial licence better fits your market entry strategy, speak with a setup adviser who understands both the DET process and MOHAP requirements before committing to a structure. The cost of changing structure post-incorporation is significantly higher than the cost of getting it right at the outset.